UEG Week 2022

What is new in anti-TNFα therapy?

Is IL-23 the super target?

Treat-to-target still alive?

What is the best dose of adalimumab in CD?

Treat-to-target with ustekinumab - why didn't it work?

Personalized therapy - de-escalation strategies

The benefit of early intervention in CD

Combination therapy: week 38 efficacy and safety data from the VEGA study

Small molecules in crohn's disease

Enhanced treatment algorithm for the management of CD

Pharmacokinetics of ustekinumab in the STARDUST trial

You can still treat severe biofailure in CD

Oral anti-integrin therapy in IBD - new data, new chances?

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

VEGA - the story continues

TYK2 Deucravacitinib in ulcerative colitis

Postoperative monitoring matters!

No matter what you use - treat early!

Treating the patient as a whole

Longterm potential benefit of a combIo therapy

Once more a shocking message: be aware of steroids!

T reg - a new therapeutic target in IBD?

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

Thinking out of the box - co-medication of the elderly

Explosion of new drugs

T reg - nowy cel terapeutyczny w IBD?

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

Explosión de nuevos fármacos

TYK2 Deucravacitinib bei Colitis ulcerosa

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Treating the patient as a whole

Small molecules nel morbo di crohn

Was tun nach der Operation?

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

VEGA - l'histoire continue

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Les résultats à long terme d'une combIothérapie

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

S1P receptor modulators

Update on JAK inhibition in UC

Update on IL-23 inhibition in UC

1st JAK inhibitor in CD - a game changer?

Upadacitinib - induction therapy in CD

Estrasimod in moderate to severe active UC

Ozanimod works in young and old UC patient

VEGA & LUCENT studies

Upadacitinib maintenance therapy - final results from U-ACHIEVE

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

The 1st JAKi in CD

Risankizumab in refractory CD patients

The era of small molecules

Selective IL-23 blockade

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

Histological response and remission induced by mirikizumab

JAK-inhibition

Selective IL-23 Blockade

Risankizumab dans la maladie de Crohn réfractaire

Upadacitinib - Induktionsdaten bei CD

VEGA & LUCENT studi clinici

JAK-Inhibition

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

The area of small molecules

Updated safety data on JAK inhibitors

Treating the elderly - closer surveillance and the importance of co-medication

Urgency - putting the focus on an important endpoint!

Steroid effects as treatment goals: quality of life and steroid free remission

Urgency matters!

New endpoints in IBD

Patient reported outcomes in IBD

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Patienten gerichtete Endpunkte bei CED

Neue Studienendpunkte in IBD

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Explosion of Spanish contributions

Explosión de las comunicaciones españolas

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Personalised therapy in IBD

Individualisierte Therapie bei CED